Who we Are
Over a decade of experience pioneering immune tolerance
Selecta Biosciences Inc. founded in 2008, is leveraging its clinically-validated ImmTORTM platform to develop antigen-specific tolerogenic therapies. With a proven ability to induce tolerance to highly immunogenic molecules, ImmTOR can be leveraged to both amplify the efficacy of biologics, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases.
At Selecta, we strive towards a common goal: to improve the lives of those who suffer from serious and debilitating diseases.